By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

ImmunoGen, Inc. 

128 Sidney Street

Cambridge  Massachusetts  02139-4239  U.S.A.
Phone: 617-995-2500 Fax: 617-995-2510


SEARCH JOBS


Industry
Biotechnology


Collaborations

GlaxoSmithKline (North Carolina) 

Raven Biotechnologies, Inc.  Partnership for the discovery and development of therapeutic MAbs for the treatment of ovarian cancer.

Medarex, Inc.  Partnership for the discovery and development of therapeutic MAbs for the treatment of ovarian cancer.





Company News
ImmunoGen (IMGN) Announces Webcast Of Presentation At The Canaccord Genuity Growth Conference 8/2/2017 8:12:47 AM
ImmunoGen (IMGN) Announces Webcast Of Presentation At The Canaccord Genuity Growth Conference 8/2/2017 6:39:17 AM
ImmunoGen (IMGN) Reports Recent Progress And Second Quarter 2017 Operating Results 7/28/2017 6:07:59 AM
ImmunoGen (IMGN) Announces Conference Call To Discuss Its Second Quarter 2017 Financial Results 7/14/2017 6:20:10 AM
ImmunoGen (IMGN) Presents Data From Phase I Study Of IMGN779 In Acute Myeloid Leukemia 6/26/2017 9:01:47 AM
ImmunoGen (IMGN) And Sanofi (SNY) Amend License Agreements 5/30/2017 8:51:35 AM
Debiopharm Enters The Field Of Antibody-Drug Conjugates Through Acquisition Of Phase II Asset From ImmunoGen (IMGN) 5/24/2017 8:47:20 AM
ImmunoGen (IMGN) Announces New Clinical Data With Mirvetuximab Soravtansine In Ovarian Cancer To Be Presented At 2017 ASCO Annual Meeting 5/18/2017 8:41:34 AM
ImmunoGen (IMGN) Reports Recent Progress And First Quarter 2017 Operating Results 5/5/2017 6:12:22 AM
ImmunoGen (IMGN) Announces Results from Mirvetuximab Soravtansine Phase 1 First-in-Human Dose-Escalation Trial Published in Cancer 5/1/2017 7:26:51 AM
12345678910...
//-->